Belite Bio, Inc (BLTE): who owns it and who trades it
As of Nov 16, 2026, BLTE insiders reported 178 open-market sales worth $40.9M and no purchases in the last 12 months, with 1% of the sale value made under pre-set 10b5-1 plans. The largest seller was Yu-Hsin Lin (CEO), with $20.8M. 5 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Belite Bio
From the latest filingsOverall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns BLTE
81 funds and institutions reported BLTE shares worth $1.4B at the end of Q2 2026, about 24% of the company. The largest holder is Darwin Global Management, Ltd. with 7.8%.
Funds and institutions (13F) 24%Everyone else 76%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.08M | 7.82% | $457M | +1% |
| Paradigm Biocapital Advisors LP | 1.23M | 3.13% | $190M | +11% |
| Rtw Investments, LP | 715,332 | 1.82% | $110M | No change |
| Millennium Management LLC | 494,564 | 1.26% | $76.2M | -13% |
| Maverick Capital Ltd | 396,311 | 1.01% | $61M | New |
| Eventide Asset Management, LLC | 390,829 | 0.99% | $60.2M | +9% |
| Deerfield Management Company, L.P. | 357,199 | 0.91% | $55M | +17% |
| Holocene Advisors, LP | 251,035 | 0.64% | $38.7M | -49% |
| Logos Global Management LP | 250,000 | 0.64% | $38.5M | New |
| Morgan Stanley | 235,071 | 0.60% | $36.2M | +17% |
| UBS Group AG | 224,989 | 0.57% | $34.6M | -71% |
| Citadel Advisors LLC | 186,168 | 0.47% | $28.7M | +9171% |
| Goldman Sachs Group Inc | 166,188 | 0.42% | $25.6M | +58% |
| Affinity Asset Advisors, LLC | 165,000 | 0.42% | $25.4M | +154% |
| Mpm Bioimpact LLC | 137,208 | 0.35% | $21.1M | +56% |
| Bank of America Corp | 124,783 | 0.32% | $19.2M | +3203% |
| Patient Square Capital LP | 110,000 | 0.28% | $16.9M | -6% |
| Duquesne Family Office LLC | 106,100 | 0.27% | $16.3M | No change |
| T. Rowe Price Associates | 105,859 | 0.27% | $16.3M | -62% |
| Jane Street Group, LLC | 65,801 | 0.17% | $10.1M | +438% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, BLTE insiders reported $0 of open-market purchases and $40.9M of sales. 1% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 12, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 500 | $162.04 | $81K | Form 4 |
| Nov 12, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 500 | $164.68 | $82.3K | Form 4 |
| Nov 12, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 500 | $166.82 | $83.4K | Form 4 |
| Nov 12, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 500 | $170.41 | $85.2K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 200 | $163.62 | $32.7K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 24 | $164.64 | $4K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 120 | $165.49 | $19.9K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 50 | $166.44 | $8.3K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 78 | $167.59 | $13.1K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 12 | $168.21 | $2K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 14 | $169.36 | $2.4K | Form 4 |
| Oct 1, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale plan | 2 | $170.02 | $340 | Form 4 |
| Sep 8, 2026 | Yu-Hsin Lin | CEO | Sale | 6,058 | $196.54 | $1.2M | Form 4 |
| Sep 8, 2026 | Yu-Hsin Lin | CEO | Sale | 8,752 | $197.36 | $1.7M | Form 4 |
| Sep 8, 2026 | Yu-Hsin Lin | CEO | Sale | 2,700 | $198.09 | $535K | Form 4 |
| Sep 8, 2026 | Yu-Hsin Lin | CEO | Sale | 2,400 | $194.33 | $466K | Form 4 |
| Sep 8, 2026 | Yu-Hsin Lin | CEO | Sale | 6,090 | $195.62 | $1.2M | Form 4 |
| Sep 8, 2026 | Hao-Yuan Chuang | CFO | Sale | 2,562 | $198.05 | $507K | Form 4 |
| Sep 8, 2026 | Hao-Yuan Chuang | CFO | Sale | 2,200 | $194.28 | $427K | Form 4 |
| Sep 8, 2026 | Hao-Yuan Chuang | CFO | Sale | 4,120 | $195.60 | $806K | Form 4 |
| Sep 8, 2026 | Hao-Yuan Chuang | CFO | Sale | 4,475 | $196.47 | $879K | Form 4 |
| Sep 8, 2026 | Hao-Yuan Chuang | CFO | Sale | 4,605 | $197.23 | $908K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 8,111 | $193.13 | $1.6M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 2,635 | $180.29 | $475K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 2,587 | $181.24 | $469K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 3,413 | $182.50 | $623K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 4,955 | $183.30 | $908K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 6,252 | $184.52 | $1.2M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 4,593 | $185.34 | $851K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 7,800 | $186.32 | $1.5M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 6,200 | $187.25 | $1.2M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 3,045 | $188.26 | $573K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 8,955 | $189.34 | $1.7M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 600 | $190.39 | $114K | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 11,080 | $191.15 | $2.1M | Form 4 |
| Sep 4, 2026 | Yu-Hsin Lin | CEO | Sale | 4,209 | $192.54 | $810K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 1,633 | $180.16 | $294K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 2,000 | $182.49 | $365K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 3,759 | $183.27 | $689K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 3,569 | $184.57 | $659K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 3,872 | $185.28 | $717K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 4,600 | $186.35 | $857K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 3,900 | $187.16 | $730K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 1,900 | $188.59 | $358K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 6,200 | $189.22 | $1.2M | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 1,800 | $190.63 | $343K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 6,200 | $191.09 | $1.2M | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 3,398 | $192.40 | $654K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 4,602 | $193.12 | $889K | Form 4 |
| Sep 4, 2026 | Hao-Yuan Chuang | CFO | Sale | 2,000 | $181.05 | $362K | Form 4 |
| Aug 12, 2026 | Hao-Yuan Chuang | CFO | Sale | 144 | $180.00 | $25.9K | Form 4 |
| Aug 12, 2026 | Hao-Yuan Chuang | CFO | Sale | 223 | $180.57 | $40.3K | Form 4 |
| Aug 12, 2026 | Yu-Hsin Lin | CEO | Sale | 142 | $180.00 | $25.6K | Form 4 |
| Jun 18, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 3,748 | $144.66 | $542K | Form 4 |
| Jun 18, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 96 | $147.11 | $14.1K | Form 4 |
| Jun 18, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 1,199 | $146.24 | $175K | Form 4 |
| Jun 18, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 4,861 | $145.43 | $707K | Form 4 |
| Jun 18, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 96 | $143.90 | $13.8K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 784 | $138.18 | $108K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 2,054 | $137.61 | $283K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 1,035 | $145.02 | $150K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 3,140 | $139.57 | $438K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 540 | $140.58 | $75.9K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 100 | $141.83 | $14.2K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 450 | $142.20 | $64K | Form 4 |
| Jun 16, 2026 | Hendrik Peter Scholl | Chief Medical Officer | Sale | 1,897 | $143.55 | $272K | Form 4 |
| May 7, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 3 | $154.61 | $464 | Form 4 |
| May 7, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 428 | $153.56 | $65.7K | Form 4 |
| May 7, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 9 | $155.25 | $1.4K | Form 4 |
| May 7, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 226 | $152.45 | $34.5K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 240 | $154.41 | $37.1K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 100 | $155.97 | $15.6K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 8 | $151.57 | $1.2K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 424 | $152.67 | $64.7K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 128 | $153.42 | $19.6K | Form 4 |
| May 6, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 100 | $156.00 | $15.6K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 68 | $158.11 | $10.8K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 155 | $157.29 | $24.4K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 173 | $155.48 | $26.9K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 363 | $154.44 | $56.1K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 120 | $153.92 | $18.5K | Form 4 |
| May 5, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 121 | $156.53 | $18.9K | Form 4 |
| May 4, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 172 | $157.49 | $27.1K | Form 4 |
| May 4, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 235 | $156.57 | $36.8K | Form 4 |
| May 4, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 325 | $155.21 | $50.4K | Form 4 |
| May 4, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 236 | $154.24 | $36.4K | Form 4 |
| May 4, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 32 | $153.50 | $4.9K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 288 | $154.38 | $44.5K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 346 | $155.48 | $53.8K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 52 | $153.89 | $8K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 82 | $156.24 | $12.8K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 106 | $157.45 | $16.7K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 65 | $158.35 | $10.3K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 38 | $159.08 | $6K | Form 4 |
| May 1, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 23 | $160.00 | $3.7K | Form 4 |
| Apr 30, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 101 | $158.15 | $16K | Form 4 |
| Apr 30, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 42 | $155.68 | $6.5K | Form 4 |
| Apr 30, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 340 | $157.37 | $53.5K | Form 4 |
| Apr 30, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 517 | $156.59 | $81K | Form 4 |
| Apr 29, 2026 | Nathan L. Mata | Chief Scientific Officer | Sale | 102 | $157.39 | $16.1K | Form 4 |
Latest 100 of 178 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Yu-Hsin Lin | Chief Executive Officer, Director | – | $20.8M | Sep 8, 2026 |
| Hao-Yuan Chuang | Chief Financial Officer, Director | – | $14M | Sep 8, 2026 |
| Hendrik Peter Scholl | Chief Medical Officer | – | $3.3M | Nov 12, 2026 |
| Nathan L. Mata | Chief Scientific Officer | – | $2.7M | May 7, 2026 |
| Wan-Shan Chen | Director | – | $198K | Apr 9, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
BLTE short interest
1.38M BLTE shares are sold short. Over the last 12 reports the number of shares short went up 16%.
As of Oct 30, 2026, 1.38M BLTE shares were sold short, up 8.9% from the report before. At the average daily volume of 138,665 shares, buying them all back would take about 10.0 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.38M | – | +9% | 138,665 | 10.0 |
| Oct 15, 2026 | 1.27M | – | +20% | 178,362 | 7.1 |
| Sep 30, 2026 | 1.06M | – | +1% | 145,206 | 7.3 |
| Sep 15, 2026 | 1.05M | – | +0% | 274,217 | 3.8 |
| Aug 31, 2026 | 1.05M | – | -6% | 141,528 | 7.4 |
| Aug 14, 2026 | 1.12M | – | -2% | 191,273 | 5.8 |
| Jul 31, 2026 | 1.13M | – | -14% | 168,803 | 6.7 |
| Jul 15, 2026 | 1.32M | 3.34% | +0% | 186,330 | 7.1 |
| Jun 30, 2026 | 1.31M | 3.34% | -1% | 247,077 | 5.3 |
| Jun 15, 2026 | 1.32M | 3.37% | +10% | 238,100 | 5.6 |
| May 29, 2026 | 1.20M | 3.05% | +1% | 242,599 | 5.0 |
| May 15, 2026 | 1.19M | 3.03% | -3% | 122,831 | 9.7 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Belite Bio financials
Famous investors that hold BLTE
5 of the 50 well-known investors we track reported holding BLTE in their latest 13F filing. The largest position is Lee Ainslie's, worth $104M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Lee Ainslie · Maverick Capital | Q3 2026 | 609,906 | $104M | 0.8% | +54% |
| Israel Englander · Millennium Management | Q3 2026 | 375,066 | $63.7M | 0.0% | -24% |
| Stanley Druckenmiller · Duquesne Family Office | Q3 2026 | 106,100 | $18M | 0.4% | No change |
| Jim Simons · Renaissance Technologies | Q3 2026 | 32,800 | $5.6M | 0.0% | -41% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 19,143 | $3.3M | 0.0% | -63% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Belite Bio, Inc (BLTE) stock
Who owns the most BLTE stock?
The largest reported owner of Belite Bio, Inc (BLTE) is Darwin Global Management, Ltd., with 7.8% of the company. In total, 81 funds and institutions reported holding BLTE at the end of Q2 2026, together about 24% of the shares. See the largest owners.
Are BLTE insiders buying or selling?
In the last 12 months, BLTE insiders reported no open-market purchases and 178 sales worth $40.9M. The latest trade was on Nov 12, 2026. See every trade.
What is the short interest in BLTE?
As of Oct 30, 2026, 1.38M BLTE shares were sold short, up 8.9% from the report before. At the average daily volume of 138,665 shares, buying them all back would take about 10.0 trading days (days to cover). See the history.
Which famous investors hold BLTE?
5 of the 50 well-known investors we track reported BLTE in their latest 13F filing, including Lee Ainslie, Israel Englander, Stanley Druckenmiller. The largest position is worth $104M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.